oasis 1 oral semaglutide 50 mg obesity nejm 2023 results Frontiers nejm Semaglutide, a glucagon-like peptide-1

Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinsons disease

Chronic anemic hypoxemia increases plasma glucagon and hepatic PCK1 mRNA in late-gestation fetal sheep

Results When compared with PEG-loxenatide 0.2 mg, the projections of outcomes over the 40-year time horizon in patients with type 2 diabetes uncontrolled on metformin showed that treatment with once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improved discounted life expectancy by 0.08 and 0.12 years, and improved discounted quality-adjusted life expectancy by 0.16 and 0.22 quality-adjusted life-years, respectively

Compare mechanism, peer-reviewed efficacy, dosing, side-effect profiles, and real Thai-clinic cost

FDA concerns

[DOI] [PubMed] [Google Scholar] 68.Tschandl Philipp, Codella Noel, Akay Beng Nisa, Argenziano Giuseppe, Braun Ralph P, Cabo Horacio, Gutman David, Halpern Allan, Helba Brian, Hofmann-Wellenhof Rainer, Lallas Aimilios, Lapins Jan, Longo Caterina, Malvehy Josep, Marchetti Michael A, Marghoob Ashfaq, Menzies Scott, Oakley Amanda, Paoli John, Puig Susana, Rinner Christoph, Rosendahl Cliff, Scope Alon, Sinz Christoph, Soyer H Peter, Thomas Luc, Zalaudek Iris, Kittler Harald